Emmessar Biotech & Nutrition Limited (EMMESSA.BO)
INR 44.98
(4.6%)
INR 44.98
(4.6%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 9.58 Million | 3.76 Million | 22.69 Million | 4.67 Million | 10.3 Million | 3.88 Million |
| Net Income | 7.49 Million | 9.66 Million | 9.31 Million | 22.54 Million | 10.01 Million | 5.8 Million |
| Depreciation & Amortization | 976 Thousand | 936 Thousand | 923 Thousand | 577.24 Thousand | 577.75 Thousand | 786.36 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 2.03 Million | -4.98 Million | 17.56 Million | -16.14 Million | 3.39 Million | -1.24 Million |
| Other non-cash items | 582 Thousand | -1.85 Million | -5.1 Million | -2.29 Million | -3.68 Million | -1.46 Million |
| Investing Cash Flow | -9.9 Million | -5.46 Million | -26.14 Million | 81.71 Thousand | -10.57 Million | -3.74 Million |
| Investments in PPE | - | -263 Thousand | -3.05 Million | -18 Thousand | -5200.00 | -7800.00 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -9.9 Million | -7.78 Million | -24.58 Million | -1.14 Million | -11.94 Million | -4.09 Million |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 1000.00 | 2.58 Million | 1.49 Million | 1.23 Million | 1.37 Million | 355.1 Thousand |
| Financing Cash Flow | 326 Thousand | - | - | - | -419.21 Thousand | 1.2 Million |
| Debt repayment | -326 Thousand | - | - | - | -419.21 Thousand | -1.2 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | 2.41 Million |
| Accounts receivables | -116 Thousand | 21 Thousand | 26.97 Million | -26.83 Million | 117.38 Thousand | -48.2 Thousand |
| Accounts payables | 91 Thousand | -216 Thousand | -4.74 Million | -3.07 Million | 2.28 Million | 5.67 Million |
| Inventory | 471 Thousand | -680 Thousand | -9000.00 | 10.81 Million | -4.2 Million | -6.41 Million |
| Other working capital | 1.59 Million | -4.11 Million | -4.65 Million | 2.94 Million | 5.2 Million | -463.13 Thousand |
| Cash at beginning of period | 118 Thousand | 1.81 Million | 5.26 Million | 503.87 Thousand | 777.33 Thousand | 636.92 Thousand |
| Cash at end of period | 61.82 Million | 118 Thousand | 1.81 Million | 5.26 Million | 503.87 Thousand | 777.33 Thousand |
| Capital Expenditure | - | -263 Thousand | -3.05 Million | -18 Thousand | -5200.00 | -7800.00 |
| Effect of forex changes on cash | - | - | - | - | 419.21 Thousand | -1.2 Million |
| Net cash flow / Change in cash | 61.7 Million | -1.7 Million | -3.44 Million | 4.76 Million | -273.46 Thousand | 140.41 Thousand |
| Free Cash Flow | 9.58 Million | 3.49 Million | 19.64 Million | 4.66 Million | 10.29 Million | 3.87 Million |
| Breakdown | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 7.49 Million | 1.28 Million | 1.97 Million | 549 Thousand | 9.66 Million | 1.96 Million |
| Depreciation & Amortization | 976 Thousand | 244 Thousand | 244 Thousand | 244 Thousand | 936 Thousand | 237 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 2.03 Million | - | - | - | -4.98 Million | - |
| Other non-cash items | 582 Thousand | -244 Thousand | -244 Thousand | -244 Thousand | -1.85 Million | -237 Thousand |
| Investing Cash Flow | -9.9 Million | - | - | - | -5.46 Million | - |
| Investments in PPE | - | - | - | - | -263 Thousand | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -9.9 Million | - | - | - | -7.78 Million | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 1000.00 | - | - | - | 2.58 Million | - |
| Financing Cash Flow | 326 Thousand | - | - | - | - | - |
| Debt repayment | -326 Thousand | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | - |
| Accounts receivables | -116 Thousand | - | - | - | 21 Thousand | - |
| Accounts payables | 91 Thousand | - | - | - | -216 Thousand | - |
| Inventory | 471 Thousand | - | - | - | -680 Thousand | - |
| Other working capital | 1.59 Million | - | - | - | -4.11 Million | - |
| Cash at beginning of period | 118 Thousand | 758 Thousand | -1.21 Million | 118 Thousand | 1.81 Million | -1.85 Million |
| Cash at end of period | 61.82 Million | 1.28 Million | 758 Thousand | 549 Thousand | 118 Thousand | 118 Thousand |
| Capital Expenditure | - | - | - | - | -263 Thousand | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 61.7 Million | 531 Thousand | 1.97 Million | 431 Thousand | -1.7 Million | 1.96 Million |
| Free Cash Flow | 9.58 Million | 1.28 Million | 1.97 Million | 549 Thousand | 3.49 Million | 1.96 Million |
MEQYF
3913
STX
4506
1376
TRANSFRE